CRISPR Therapeutics AG (CRSP) Amortization of Deferred Charges (2016)

CRISPR Therapeutics AG has disclosed Amortization of Deferred Charges across 1 years of filings, most recently posting $8.0 million for Q1 2016.

• Amortization of Deferred Charges for Q1 2016 came in at $8.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2016 was $8.0 million (changed N/A YoY), and the FY2016 annual result was $8.0 million, up 8198.97% from the prior year.
• Amortization of Deferred Charges came in at $8.0 million for Q1 2016 at CRISPR Therapeutics AG.
• In the past five years, Amortization of Deferred Charges ranged from a high of $8.0 million in Q1 2016 to a low of $8.0 million in Q1 2016.